Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which was nominated as development candidate last year. SAN-2668 is a GABA-A receptor positive allosteric modulator under development for the treatment of severe pediatric epilepsies, including developmental and epileptic encephalopathies (DEEs).